104 related articles for article (PubMed ID: 36524517)
1. Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation.
Barabino L; Galitzia A; Murru R; Caocci G; Targhetta C; Greco M; Angioni G; Mulas O; Vacca A; Piras E; Frau V; Costa A; La Nasa G
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8984-8989. PubMed ID: 36524517
[TBL] [Abstract][Full Text] [Related]
2. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
3. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
Nagafuji K
Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
[TBL] [Abstract][Full Text] [Related]
4. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
J Infect Chemother; 2023 Mar; 29(3):274-280. PubMed ID: 36442827
[TBL] [Abstract][Full Text] [Related]
5. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
6. Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Henig I; Isenberg J; Yehudai-Ofir D; Leiba R; Ringelstein-Harlev S; Ram R; Avni B; Amit O; Grisariu S; Azoulay T; Slouzkey I; Zuckerman T
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112688
[TBL] [Abstract][Full Text] [Related]
7. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
[TBL] [Abstract][Full Text] [Related]
8. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
[TBL] [Abstract][Full Text] [Related]
11. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.
Chaekal OK; Gomez-Arteaga A; Chen Z; Soave R; Shore T; Mayer S; Phillips A; Hsu JM; Drelick A; Kodiyanplakkal RPL; Plate M; Satlin MJ; van Besien K
Transplant Cell Ther; 2022 Sep; 28(9):618.e1-618.e10. PubMed ID: 35724850
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
[TBL] [Abstract][Full Text] [Related]
15. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation.
Yeshurun M; Pasvolsky O; Shargian L; Yahav D; Ben-Zvi H; Rubinstein M; Sela-Navon M; Wolach O; Raanani P; Rozovski U
Clin Microbiol Infect; 2022 Feb; 28(2):303.e1-303.e4. PubMed ID: 34715348
[TBL] [Abstract][Full Text] [Related]
16. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
Ram R; Hagin D; Kikozashvilli N; Freund T; Amit O; Bar-On Y; Beyar-Katz O; Shefer G; Moshiashvili MM; Karni C; Gold R; Kay S; Glait-Santar C; Eshel R; Perry C; Avivi I; Apel A; Benyamini N; Shasha D; Ben-Ami R
Transplant Cell Ther; 2021 Sep; 27(9):788-794. PubMed ID: 34214738
[TBL] [Abstract][Full Text] [Related]
17. Elevated CD21
Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
[TBL] [Abstract][Full Text] [Related]
18. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
19. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study.
Ngo D; Chen J; Tinajero J; Aribi A; Arslan S; Marcucci G; Nakamura R; Al Malki MM; Forman SJ; Dadwal S; Ali H
Stem Cell Res Ther; 2023 Apr; 14(1):95. PubMed ID: 37072867
[TBL] [Abstract][Full Text] [Related]
20. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
